PMID- 28107570
OWN - NLM
STAT- MEDLINE
DCOM- 20180402
LR  - 20180402
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Linking)
VI  - 31
IP  - 6
DP  - 2017 Jun
TI  - Efficacy and safety of interleukin-17 antagonists in patients with plaque 
      psoriasis: a meta-analysis from phase 3 randomized controlled trials.
PG  - 992-1003
LID - 10.1111/jdv.14125 [doi]
AB  - BACKGROUND: The interleukin-17 (IL-17) cytokine pathway plays a key role in the 
      development of psoriasis. Antibodies targeting IL-17 or blocking its receptor may 
      be a new therapeutic approach for psoriasis. To assist treatment selection in 
      daily practice, it is essential to understand the benefit and risk profile of 
      IL-17 antagonists. OBJECTIVE: We performed a meta-analysis to evaluate the 
      efficacy and safety of IL-17 antagonists in patients with psoriasis. METHODS: We 
      searched a number of databases for relevant randomized controlled trials (RCTs) 
      published before May 2016. The following outcomes were evaluated: Psoriasis Area 
      and Severity Index (PASI) 75, 90, 100 response, Investigator's Global Assessment 
      (IGA) score of 0 or 1 response, adverse events (AEs) and withdrawals. The 
      meta-analysis was performed using Review Manager 5.2 software. RESULTS: Nine RCTs 
      with 5951 patients were included. IL-17 antagonists achieved higher PASI 75, 90, 
      100 response rates and Dermatology Life Quality Index 0 or 1 response rates than 
      placebo and a lower incidence of discontinuations due to lack of efficacy. In the 
      safety analysis, no significant differences were found between the IL-17 
      antagonists and placebo in the proportion of patients with serious AEs, 
      cardiovascular disease and discontinuations due to AEs. However, IL-17 
      antagonists were associated with a higher proportion of patients with any AEs and 
      infections than placebo. CONCLUSION: IL-17 antagonists were effective, with an 
      acceptable safety profile, for patients with plaque psoriasis. Vigilance because 
      of the potential for infection will be necessary for IL-17 antagonists.
CI  - (c) 2017 European Academy of Dermatology and Venereology.
FAU - Wu, D
AU  - Wu D
AD  - Second Departments of Rheumatology, Shengjing Hospital of China Medical 
      University, Shenyang, Liaoning, China.
FAU - Hou, S-Y
AU  - Hou SY
AD  - Intensive Care Unit, The People's Hospital of Liaoning Province, Shenyang, 
      Liaoning, China.
FAU - Zhao, S
AU  - Zhao S
AD  - Second Departments of Rheumatology, Shengjing Hospital of China Medical 
      University, Shenyang, Liaoning, China.
FAU - Hou, L-X
AU  - Hou LX
AD  - Second Departments of Rheumatology, Shengjing Hospital of China Medical 
      University, Shenyang, Liaoning, China.
FAU - Jiao, T
AU  - Jiao T
AD  - Second Departments of Rheumatology, Shengjing Hospital of China Medical 
      University, Shenyang, Liaoning, China.
FAU - Xu, N-N
AU  - Xu NN
AD  - Second Departments of Rheumatology, Shengjing Hospital of China Medical 
      University, Shenyang, Liaoning, China.
FAU - Zhang, N
AU  - Zhang N
AD  - Second Departments of Rheumatology, Shengjing Hospital of China Medical 
      University, Shenyang, Liaoning, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20170208
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
RN  - 0 (Interleukin-17)
SB  - IM
MH  - Clinical Trials, Phase III as Topic
MH  - Humans
MH  - Interleukin-17/*antagonists & inhibitors
MH  - Psoriasis/*drug therapy
MH  - Randomized Controlled Trials as Topic
EDAT- 2017/01/21 06:00
MHDA- 2018/04/03 06:00
CRDT- 2017/01/21 06:00
PHST- 2016/08/27 00:00 [received]
PHST- 2017/01/03 00:00 [accepted]
PHST- 2017/01/21 06:00 [pubmed]
PHST- 2018/04/03 06:00 [medline]
PHST- 2017/01/21 06:00 [entrez]
AID - 10.1111/jdv.14125 [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2017 Jun;31(6):992-1003. doi: 10.1111/jdv.14125. 
      Epub 2017 Feb 8.